Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Sequins As Novel Internal Controls to Improve Genomic Analysis

By LabMedica International staff writers
Posted on 16 Aug 2016
Print article
Image: Sequins are small stretches of synthetic DNA to be added as a standardization control to a DNA sample during sequencing, helping analyze the large data files generated for genomic analysis. The technology is based on the notion of mirror image DNA. Sequins are essentially “mirror” images of natural DNA sequences. They behave like natural DNA sequences but can be easily recognized as synthetic (Photo courtesy of Chris Hammang, Garvan Institute of Medical Research).
Image: Sequins are small stretches of synthetic DNA to be added as a standardization control to a DNA sample during sequencing, helping analyze the large data files generated for genomic analysis. The technology is based on the notion of mirror image DNA. Sequins are essentially “mirror” images of natural DNA sequences. They behave like natural DNA sequences but can be easily recognized as synthetic (Photo courtesy of Chris Hammang, Garvan Institute of Medical Research).
Researchers have developed an intuitive technology called “Sequins” – synthetic “mirror” DNA sequences that reflect the human genome and can be used to better map, navigate, and analyze complexity within the genome. Currently human genome Sequins are freely available for research.

Scientists at the Garvan Institute of Medical Research (Darlinghurst, Sydney, NSW, Australia) developed the new technology. “Human genome sequencing is transforming biomedical research and healthcare,” said Dr. Tim Mercer, who led the development of Sequins, “And as genome sequencing is being increasingly used to diagnose disease, it is more important than ever that researchers and clinicians understand the accuracy of the genomic data they are looking at.”

Dr. Mercer and his team came up with the idea of adding Sequins, small stretches of synthetic DNA, to a patient’s DNA sample during sequencing. These Sequins (or sequencing spike-ins) then act as internal standards, helping researchers analyze the large data files generated during genome sequencing. The technology is based on an intuitively simple concept: the notion of mirror image DNA. “Sequins are, essentially, mirror images of natural DNA sequences. Like us, the genome has a ‘handedness’, and just as our right hand differs from our left hand, sequins differ from natural genome sequences. So sequins behave just like natural genome sequences, but they can be easily recognized as synthetic,” said Dr. Mercer.

When added to a sequencing reaction, sequins provide internal controls with which to assess the sensitivity and accuracy of genome sequencing. “A whole series of steps, first in the lab and then on the computer, are required to sequence a person’s genome or the genes that are expressed in different cells. Sequins are with the person’s DNA every step of the way: responding just as real DNA does at each step, yet unmistakably different from that real DNA. This allows a scientist to assess, and optimize, these different steps.”

Because sequins are added to each individual sample, they can provide a sample-by-sample assessment – something that has not previously been possible. “Sequins are the first technology to allow diagnostic statistics to be applied to each individual genome sequencing test,” said Dr. Mercer, “and we anticipate that their use will improve the reliability and sensitivity of genetic disease diagnosis.”

Cancer diagnosis is one area in which using Sequins should lead to improvements. “Incorporating Sequins into clinical tests for cancer diagnosis will increase the reliability of an individual diagnostic readout, reducing incorrect diagnoses and giving clinicians greater confidence in deciding the best course of treatment for their patient,” said Dr. Mercer.

Using Sequins will also make it possible to directly compare genomic data from research institutes and sequencing centers worldwide. “Sequins bring DNA sequencing to clinical standard, and will be an essential platform for genomic research and medicine,” said co-author Prof. John Mattick, Garvan’s executive director, “This is another important step in advancing Garvan’s mission to bring genomics to the clinic.”

The potential applications of Sequins are many. Because all genomes, from bacteria to human, have handedness, sequins can be similarly designed for any organism, or for almost any next-generation sequencing (NGS) application.

The Sequins technology is described in two linked studies, by Hardwick SA et al and by Deveson IW et al, both published August 8, 2016, in the journal Nature Methods.

Related Links:
Garvan Institute of Medical Research


Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Chagas Disease Test
LIAISON Chagas
New
FOB+Transferrin+Calprotectin+Lactoferrin Test
CerTest FOB+Transferrin+Calprotectin+Lactoferrin Combo Test

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.